| Literature DB >> 35310102 |
Feng Gao1, Wei Zhao2, Yu Zheng3, Yu Duan4, Ming Ji1, Guangwu Lin1, Zhenfang Zhu1.
Abstract
Objective: This study aimed to investigate the feasibility of preoperative intravoxel incoherent motion (IVIM) MRI for the screening of high-risk patients with moyamoya disease (MMD) who may develop postoperative cerebral hyperperfusion syndrome (CHS).Entities:
Keywords: magnetic resonance imaging; microvascular circulation; moyamoya disease; perfusion imaging; surgery
Year: 2022 PMID: 35310102 PMCID: PMC8924456 DOI: 10.3389/fnins.2022.826021
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
MRI scanning sequences and parameters.
| TR/TE (ms) | Thickness (mm) | Flip angle (°) | Intersection gap | TA | FOV (cm2) | Matrix | ||
| T1WI | 230/2.46 | 5 | 70 | 30% | 25 s | 22 × 22 | 256 × 192 | / |
| T2WI | 5,000/117 | 5 | 90 | 30% | 54 s | 22 × 22 | 384 × 281 | / |
| FLAIR | 8,000/85 | 5 | 140 | 20% | 1 min 36 s | 22 × 22 | 256 × 162 | / |
| DWI | 1,300/62 | 5 | 192 | 30% | 30 s | 24 × 24 | 192 × 192 | 0.1000 |
| TOF | 21/3.43 | 1 | 18 | −18.75% | 5 min 13 s | 22 × 22 | 320 × 180 | / |
| IVIM | 5,100/92 | 5 | / | 30% | 5 min 22 s | 22 × 22 | 130 × 130 | 16 |
TR, time of repetition; TE, time of echo; FOV, field of view; TA, time of acquisition; FLAIR, fluid-attenuated inversion-recovery sequence; DWI, diffusion-weighted imaging; IVIM, intravoxel incoherent motion. The 16 b-values are 0, 20, 40, 80, 110, 140, 170, 200, 300, 400, 500, 600, 700, 800, 900, and 1,000 s/mm
FIGURE 1Intravoxel incoherent motion MRI imaging obtained after post-processing (the columns show three different levels, peripheral white matter level, basal ganglia level, cerebellar hemisphere level; the line shows four different IVIM parameters, ADC, D, f, D*value). (A–C) Image of ADC value; (D–F) image of D-value; (G–I) image of f value; (J–L) image of D* value.
FIGURE 2The placement of ROIs on IVIM images in three different level. (A) peripheral white matter level; (B) basal ganglia level; (C) cerebellar hemisphere level. A total of 22 ROIs were placed symmetrically on the three transverse images.
Examination results of the MMD and control groups.
| Control | MMD |
| ||
| Sex (n) | χ2 = 0.671 | 0.413 | ||
| Male (n) | 10 | 12 | ||
| Female (n) | 14 | 12 | ||
| Age (Year) | 43.67 ± 8.499 | 41.67 ± 10.606 | 0.311 | |
|
| ||||
| rADC | 1.183 ± 0.091 | 1.202 ± 0.142 | 0.430 | |
| rf | 1.345 ± 0.211 | 1.229 ± 0.211 | 0.008 | |
| rD | 1.181 ± 0.095 | 1.212 ± 0.124 | 0.179 | |
| fD* | 1.045 ± 0.173 | 1.080 ± 0.169 | 0.328 | |
|
| ||||
| ADC (μm2/s)(× 106) | 687.396 ± 38.176 | 700.354 ± 55.802 | 0.187 | |
| f (μm2/s)(× 103) | 58.454 ± 14.288 | 54.623 ± 8.566 | 0.115 | |
| D (μm2/s)(× 106) | 657.654 ± 35.982 | 658.690 ± 25.632 | 0.871 | |
| D* (μm2/s)(× 104) | 97.746 ± 15.869 | 103.225 ± 14.969 | 0.085 |
ADC, apparent diffusion coefficient; D, diffusion coefficient; D*, pseudo-diffusion coefficient; f, perfusion fraction.
Clinical characteristics of the patients in the CHS and non-CHS groups.
| CHS | Non-CHS |
| ||
| No. of patients (%) | 27 (21.77%) | 97 (78.23%) | ||
| Age (Year) | 46.741 ± 11.918 | 42.258 ± 10.969 | 0.068 | |
| Sex | χ2 = 0.987 | 0.321 | ||
| Male (n) | 11 | 50 | ||
| Female (n) | 16 | 47 | ||
| Hypertension | 13 | 39 | χ2 = 0.547 | 0.459 |
| Diabetes | 11 | 32 | χ2 = 0.560 | 0.454 |
| Matsushima types | χ2 = 11.194 | 0.048 | ||
| I | 2 | 6 | ||
| II | 2 | 10 | ||
| III | 7 | 15 | ||
| IV | 5 | 14 | ||
| V | 8 | 12 | ||
| VI | 3 | 40 | ||
| Suzuki stages | χ2 = 2.992 | 0.559 | ||
| 1 | 0 | 0 | ||
| 2 | 2 | 4 | ||
| 3 | 11 | 30 | ||
| 4 | 7 | 41 | ||
| 5 | 7 | 21 | ||
| 6 | 0 | 1 |
CHS, cerebral hyperperfusion syndrome; non-CHS, non-cerebral hyperperfusion syndrome.
Preoperative microvascular perfusion status of the CHS and non-CHS groups.
| Non-CHS | CHS |
| ||
|
| ||||
| rADC-ACA | 1.155 ± 0.12 | 1.184 ± 0.087 | 0.258 | |
| rADC-MCA | 1.267 ± 0.327 | 1.309 ± 0.163 | 0.522 | |
| rADC-PCA | 1.228 ± 0.160 | 1.293 ± 0.191 | 0.075 | |
| rf-ACA | 1.090 ± 0.275 | 1.294 ± 0.295 | 0.001 | |
| rf-MCA | 1.288 ± 0.296 | 1.551 ± 0.371 | 0.000 | |
| rf-PCA | 1.130 ± 0.317 | 1.328 ± 0.331 | 0.005 | |
| rD-ACA | 1.172 ± 0.124 | 1.181 ± 0.077 | 0.723 | |
| rD-MCA | 1.257 ± 0.175 | 1.303 ± 0.154 | 0.218 | |
| rD-PCA | 1.242 ± 0.154 | 1.292 ± 0.193 | 0.165 | |
| rD*-ACA | 1.064 ± 0.219 | 1.100 ± 0.257 | 0.463 | |
| rD*-MCA | 1.083 ± 0.227 | 1.141 ± 0.333 | 0.295 | |
| rD*-PCA | 0.963 ± 0.205 | 0.968 ± 0.185 | 0.917 | |
| rfD*-ACA | 1.175 ± 0.457 | 1.441 ± 0.556 | 0.012 | |
| rfD*-MCA | 1.411 ± 0.533 | 1.785 ± 0.732 | 0.004 | |
| rfD*-PCA | 1.102 ± 0.482 | 1.287 ± 0.422 | 0.073 | |
|
| ||||
| rADC-ACA | 1.152 ± 0.108 | 1.162 ± 0.097 | 0.672 | |
| rADC-MCA | 1.199 ± 0.126 | 1.224 ± 0.136 | 0.361 | |
| rADC-PCA | 1.228 ± 0.213 | 1.234 ± 0.172 | 0.892 | |
| rf-ACA | 1.109 ± 0.236 | 1.210 ± 0.212 | 0.048 | |
| rf-MCA | 1.278 ± 0.352 | 1.346 ± 0.291 | 0.360 | |
| rf-PCA | 1.143 ± 0.286 | 1.237 ± 0.251 | 0.122 | |
| rD-ACA | 1.162 ± 0.102 | 1.164 ± 0.095 | 0.923 | |
| rD-MCA | 1.207 ± 0.123 | 1.224 ± 0.130 | 0.534 | |
| rD-PCA | 1.251 ± 0.220 | 1.232 ± 0.173 | 0.677 | |
| rD*-ACA | 1.052 ± 0.184 | 1.090 ± 0.236 | 0.448 | |
| rD*-MCA | 1.078 ± 0.180 | 1.076 ± 0.205 | 0.976 | |
| rD*-PCA | 0.988 ± 0.207 | 0.958 ± 0.214 | 0.509 | |
| rfD*-ACA | 1.164 ± 0.309 | 1.331 ± 0.426 | 0.066 | |
| rfD*-MCA | 1.385 ± 0.486 | 1.465 ± 0.466 | 0.444 | |
| rfD*-PCA | 1.127 ± 0.354 | 1.202 ± 0.430 | 0.354 |
ACA, anterior cerebral artery supply area; MCA, middle cerebral artery supply area; PCA, posterior cerebral artery supply area.
Sensitivity and specificity of diagnostic thresholds for different diagnostic indicators.
| Threshold value | Sensitivity | Specificity | |
|
| |||
| rf-ACA | 1.1548 | 0.704 | 0.639 |
| rf-MCA | 1.3787 | 0.778 | 0.701 |
| rf-PCA | 1.2059 | 0.667 | 0.629 |
| rfD*-ACA | 1.223 | 0.630 | 0.598 |
| rfD*-MCA | 1.558 | 0.630 | 0.732 |
| rf-ACA | 1.0951 | 0.630 | 0.505 |
ACA, anterior cerebral artery supply area; MCA, middle cerebral artery supply area; PCA, posterior cerebral artery supply area.
FIGURE 3ROC curve of rfD* in the ACA, MCA supply areas of the ipsilateral hemisphere, rf in the ACA, MCA, PCA supply areas of the ipsilateral hemisphere and in the ACA supply area of the contralateral hemisphere for predicting postoperative CHS. The AUCs of rf in the ACA, MCA, and PCA supply areas of the ipsilateral hemisphere for predicting postoperative CHS were 0.700, 0.733, and 0.701, respectively. The AUC for rf in the ACA supply area in the contralateral hemisphere was 0.625 for predicting postoperative CHS. The AUC for rfD* in the ACA and MCA supply area in the ipsilateral hemisphere for predicting postoperative CHS were 0.654 and 0.680.